169447-99-8

Upstream product

• 169447-98-7 1-benzyl-3(S)-(2-methylthioethyl)piperazine-2,5-dione 
• 24424-99-5 di-tert-butyl dicarbonate 
• 660862-41-9 1-Benzyl-3-(S)-(2-methylsulfanyl-ethyl)-piperazine 

Downstream Products

• 740806-58-0 1-Benzyl-3-(S)-(2-methylsulfonyl-ethyl)-4-tert-butoxycarbonylpiperazine 

Relevant academic research and scientific papers

Substituted piperazines

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Inhibitors of farnesyl-protein transferase

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras. The compounds of formula A are representative of the compounds of the present invention: STR1